Free Trial

Edesa Biotech (EDSA) Competitors

Edesa Biotech logo
$2.46 -0.08 (-3.15%)
Closing price 03:56 PM Eastern
Extended Trading
$2.52 +0.06 (+2.64%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EDSA vs. STRO, PRLD, BYSI, ABVC, GANX, ARTV, TVRD, RLMD, DTIL, and INKT

Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Sutro Biopharma (STRO), Prelude Therapeutics (PRLD), BeyondSpring (BYSI), ABVC BioPharma (ABVC), Gain Therapeutics (GANX), Artiva Biotherapeutics (ARTV), Tvardi Therapeutics (TVRD), Relmada Therapeutics (RLMD), Precision BioSciences (DTIL), and MiNK Therapeutics (INKT). These companies are all part of the "pharmaceutical products" industry.

Edesa Biotech vs. Its Competitors

Sutro Biopharma (NASDAQ:STRO) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Sutro Biopharma has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500.

Edesa Biotech has a net margin of 0.00% compared to Sutro Biopharma's net margin of -201.32%. Edesa Biotech's return on equity of -162.95% beat Sutro Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sutro Biopharma-201.32% -852.70% -58.67%
Edesa Biotech N/A -162.95%-60.33%

In the previous week, Sutro Biopharma had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Sutro Biopharma and 1 mentions for Edesa Biotech. Sutro Biopharma's average media sentiment score of 0.83 beat Edesa Biotech's score of 0.64 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Sutro Biopharma Positive
Edesa Biotech Positive

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 3.6% of Sutro Biopharma shares are held by insiders. Comparatively, 22.6% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sutro Biopharma presently has a consensus price target of $4.47, indicating a potential upside of 407.17%. Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 103.25%. Given Sutro Biopharma's higher possible upside, equities research analysts clearly believe Sutro Biopharma is more favorable than Edesa Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma
2 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Edesa Biotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Edesa Biotech has lower revenue, but higher earnings than Sutro Biopharma. Edesa Biotech is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$104.47M0.71-$227.46M-$2.53-0.35
Edesa BiotechN/AN/A-$6.17M-$1.32-1.86

Summary

Sutro Biopharma beats Edesa Biotech on 9 of the 16 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$17.31M$3.38B$6.13B$10.46B
Dividend YieldN/A2.30%5.73%4.78%
P/E Ratio-1.8623.0785.1527.20
Price / SalesN/A446.16574.61178.68
Price / CashN/A46.1137.3961.86
Price / Book4.0310.5012.396.65
Net Income-$6.17M-$52.47M$3.32B$276.79M
7 Day Performance-5.75%-1.00%-0.24%-1.51%
1 Month PerformanceN/A14.49%9.56%5.46%
1 Year Performance-39.56%13.92%71.67%36.25%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDSA
Edesa Biotech
2.4263 of 5 stars
$2.46
-3.1%
$5.00
+103.3%
-38.3%$17.31MN/A-1.8620News Coverage
STRO
Sutro Biopharma
4.1277 of 5 stars
$0.82
-0.9%
$4.47
+444.1%
-79.6%$69.68M$62.04M-0.32240News Coverage
Gap Up
PRLD
Prelude Therapeutics
3.4044 of 5 stars
$1.23
-1.9%
$4.00
+226.3%
-28.8%$69.34M$7M-0.75120
BYSI
BeyondSpring
N/A$1.70
-0.6%
N/A-33.7%$68.56M$1.75M0.0080News Coverage
Gap Up
ABVC
ABVC BioPharma
0.6265 of 5 stars
$2.91
-1.9%
N/A+394.0%$68.53M$510K-17.1230
GANX
Gain Therapeutics
3.0936 of 5 stars
$1.93
+1.3%
$7.86
+308.2%
-22.1%$68.16M$50K-3.0120News Coverage
Analyst Forecast
Gap Up
ARTV
Artiva Biotherapeutics
3.378 of 5 stars
$2.78
+1.5%
$17.00
+511.5%
-76.1%$67.92M$250K0.0081News Coverage
TVRD
Tvardi Therapeutics
2.5344 of 5 stars
$6.99
+4.5%
$55.50
+694.0%
N/A$65.57M$7.14M0.0080Trending News
Analyst Downgrade
Analyst Revision
High Trading Volume
RLMD
Relmada Therapeutics
2.7699 of 5 stars
$1.95
-3.5%
$1.00
-48.7%
-40.5%$64.72MN/A-0.8810
DTIL
Precision BioSciences
3.8434 of 5 stars
$5.44
-2.2%
$47.00
+764.0%
-26.1%$64.14M$68.70M-0.62200
INKT
MiNK Therapeutics
2.6166 of 5 stars
$14.02
-0.5%
$37.50
+167.5%
+122.3%$63.37MN/A-4.8730

Related Companies and Tools


This page (NASDAQ:EDSA) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners